76% of the GBM tumors included in this analysis (n = 428) were CDKN2A deficient, with homozygous and heterozygous deletions being present on the 57% (n = 322) and 19% (n = 106) of them, respectively. The gene discussed is CDKN2A; the disease is glioblastoma.